Ann: Actinogen awarded UK Innovation Passport for Xanamem, page-24

Hi Mate,

No worries! I actually just posted it on DXB board as well, because quite a few new folk over there too & ILAP Passport was awarded some time ago, so maybe not aware of the implications either?

ILAP Passport only originated in 2021. Here is a paper from 2022, so the numbers will reflect that. What is interesting is the number of ILAP Passports that were awarded other fast track pathways to market & access for patients (sorry you will need to copy that link into your browser).

https://www.valueinhealthjournal.com/article/S1098-3015(22)03527-6/fulltext

It’s also beneficial during trials, so it’s not just a “down the track thing” & DXB already have a licensing agreement for the UK, EU, Canada, AUS & NZ. So to my thinking, a potential Accelerated Approval on succesful trials is also a plus for any Big Pharma interested in licensing the drug in that jurisdiction.

Again, this isn’t cross promotion, both companies have been awarded ILAP Passport & I think it is helpful to maybe keep your eye on that. A little further along in a Ph3, but I think a successful Ph2 for ACW, it’s going to be really helpful regardless with a Ph3.

Hope that helps too